These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21782318)

  • 1. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).
    Mangera A; Andersson KE; Apostolidis A; Chapple C; Dasgupta P; Giannantoni A; Gravas S; Madersbacher S
    Eur Urol; 2011 Oct; 60(4):784-95. PubMed ID: 21782318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
    Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
    Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
    Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
    J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.
    Chung E
    Expert Opin Biol Ther; 2015 Jan; 15(1):95-102. PubMed ID: 25347039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
    Ravindra P; Jackson BL; Parkinson RJ
    BJU Int; 2013 Jul; 112(1):94-9. PubMed ID: 23490404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AbobotulinumtoxinA for the treatment of overactive bladder.
    Flint R; Rantell A; Cardozo L
    Expert Opin Biol Ther; 2018 Oct; 18(10):1005-1013. PubMed ID: 30105941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.
    Apostolidis A; Dasgupta P; Denys P; Elneil S; Fowler CJ; Giannantoni A; Karsenty G; Schulte-Baukloh H; Schurch B; Wyndaele JJ;
    Eur Urol; 2009 Jan; 55(1):100-19. PubMed ID: 18823697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin-what urologic uses does the data support?
    Seth J; Khan MS; Dasgupta P; Sahai A
    Curr Urol Rep; 2013 Jun; 14(3):227-34. PubMed ID: 23625366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin injection for lower urinary tract dysfunction.
    Kuo YC; Kuo HC
    Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of botulinum toxin A in treating neurogenic bladder.
    Weckx F; Tutolo M; De Ridder D; Van der Aa F
    Transl Androl Urol; 2016 Feb; 5(1):63-71. PubMed ID: 26904413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity.
    Behr-Roussel D; Oger S; Pignol B; Pham E; Le Maux A; Chabrier PE; Caisey S; Compagnie S; Picaut P; Bernabé J; Alexandre L; Giuliano F; Denys P
    Eur Urol; 2012 May; 61(5):1054-61. PubMed ID: 22341129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
    Tullman M; Chartier-Kastler E; Kohan A; Keppenne V; Brucker BM; Egerdie B; Mandle M; Nicandro JP; Jenkins B; Denys P
    Neurology; 2018 Aug; 91(7):e657-e665. PubMed ID: 30030330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum Toxins Type A (Bont-A) in the Management of Lower Limb Spasticity in Children: A Systematic Literature Review and Bayesian Network Meta-analysis.
    Guyot P; Kalyvas C; Mamane C; Danchenko N
    J Child Neurol; 2019 Jun; 34(7):371-381. PubMed ID: 30803305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum Toxin Use in Neurourology.
    Peyronnet B; Gamé X; Vurture G; Nitti VW; Brucker BM
    Rev Urol; 2018; 20(2):84-93. PubMed ID: 30288145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction.
    Kuo HC
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.